Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | F10 | P00742 | 1/20 | 0.38 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.37 |
| ▸ | LSS | P48449 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | F11 | P03951 | 1/20 | 0.36 |
| ▸ | PLK1 | P53350 | 2/20 | 0.35 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3944786 | 1.00 | NPC1 (0.40) | NPC1RAB9AHTTF10KLKB1 | |
| SCHEMBL3938405 | 0.93 | F10 (0.38) | NPC1RAB9AHTTF10KLKB1 | |
| SCHEMBL5857073 | 0.93 | F10 (0.38) | NPC1RAB9AHTTF10KLKB1 | |
| SCHEMBL3944829 | 0.92 | F10 (0.40) | NPC1RAB9AHTTF10ALOX15 | |
| SCHEMBL5858272 | 0.92 | F10 (0.40) | NPC1RAB9AHTTF10ALOX15 | |
| SCHEMBL3943456 | 0.88 | NPC1 (0.40) | NPC1RAB9AHTTALOX15P2RX3 | |
| SCHEMBL5857122 | 0.88 | NPC1 (0.40) | NPC1RAB9AHTTALOX15P2RX3 | |
| SCHEMBL3944120 | 0.87 | NPC1 (0.40) | NPC1RAB9AHTTALOX15P2RX3 | |
| SCHEMBL5858115 | 0.87 | NPC1 (0.40) | NPC1RAB9AHTTALOX15P2RX3 | |
| SCHEMBL3933106 | 0.87 | NPC1 (0.40) | NPC1RAB9AHTTALOX15P2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7148249-B2 | Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-12-12 | — | — | US | disclosed |
| US-20050054710-A1 | Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054710-A1 | Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments | CDK1, CDK2, CDK3 | NPC1 4723/4885RAB9A 3709/4885HTT 4263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.